Sanofi Genzyme has announced that the Scottish Medicines Consortium (SMC) has accepted Jevtana® (cabazitaxel) for routine use in NHS Scotland for the treatment of metastatic hormone-refractory prostate cancer (mHRPC).
In Scotland, nearly 1 in 2 men will be affected by some form of prostate disease at some stage of their lives and approximately 1 in 11 men are likely to develop prostate cancer, the most common cancer in men in Scotland. In time, most prostate cancers become resistant to hormone therapy and continue to grow despite treatment. Jevtana is the only remaining chemotherapy option available on the NHS for advanced prostate cancer that is not responsive to hormone therapies, following initial chemotherapy (docetaxel).
Today’s SMC announcement comes after Sanofi Genzyme provided an updated submission to the SMC who rejected its initial application in June. Jevtana is already available in England, Wales and Northern Ireland.
Roger Wotton, Chairman at prostate cancer patients’ charity TACKLE, said: “Any extension of time a man with prostate cancer is able to get back to be with family and friends is highly important. The availability of Jevtana means men in Scotland now have an alternative effective treatment option. Likewise, physicians now have another medicine in their arsenal to treat patients.”
Dr Jasmin Hussein, Oncology & Immunology Franchise Director UK & Ireland at Sanofi Genzyme, said: ”Through ongoing collaboration our treatment can now be accessed by all doctors who treat patients with metastatic hormone-refractory prostate cancer in the country.”